Theravance Biopharma, Inc. (TBPH)

18.16 +0.48 (+2.71%) USD  |  NASDAQ  |  Dec 12, 16:00
18.31 +0.15 (+0.83%) After-Hours: 20:00
More

Theravance Biopharma Research and Development Expense (Annual): 36.04M for Dec. 31, 2024

Research and Development Expense (Annual) Chart

View Research and Development Expense (Annual) for TBPH.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Research and Development Expense (Annual) Chart
Start Trial

Historical Data

View Historical Data
Start Trial

R&D Expense Definition

View R&D Expense Definition
Start Trial

R&D expense is a line item from many companies' income statements.

Read full definition.

Research and Development Expense (Annual) Range, Past 5 Years

View Research and Development Expense (Annual) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Research and Development Expense (Annual) Benchmarks

View Research and Development Expense (Annual) Benchmarks
Start Trial
Corcept Therapeutics, Inc. 246.89M
Assertio Holdings, Inc. 3.822M
Skye Bioscience, Inc. 18.70M
FibroGen, Inc. 95.69M
VYNE Therapeutics, Inc. 30.95M